Berman Capital Advisors’s Health Catalyst HCAT Stock Holding History

Berman Capital Advisors’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2K	Buy	+46	New	+$2.51K	﹤0.01%	1694

Other funds holding HCAT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Berman Capital Advisors's HCAT Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Health Catalyst (HCAT) in Q3 2021: 46 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #1694 among its holdings.

198 funds tracked by Wall St. Rank hold HCAT as of Q3 2021.

Berman Capital Advisors held 46 shares of Health Catalyst worth $2K as of Q3 2021.
Health Catalyst was a new Berman Capital Advisors position in Q3 2021.
Health Catalyst made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1694 holding.
198 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.